Registry of Hospitalized Patients Treated With Fondaparinux
NCT ID: NCT00549705
Last Updated: 2009-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
220 participants
OBSERVATIONAL
2007-07-31
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism
NCT00413504
Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients
NCT00493896
The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients
NCT00531843
A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery
NCT00843492
Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
NCT01499953
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Recent data have further demonstrated the efficacy and safety of Fondaparinux in VTE and ACS, expanding its use in clinical practice. We aim to: 1) determine how Fondaparinux is being used in a "real life" clinical setting, a tertiary-care academic medical center (BWH), and 2) assess the associated clinical outcomes at 90 days after initiation of Fondaparinux.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Brigham and Women's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Brigham and Women's Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Samuel Z Goldhaber, MD
Role: PRINCIPAL_INVESTIGATOR
Brigham and Women's Hospital
Related Links
Access external resources that provide additional context or updates about the study.
North American Thrombosis Forum (NATF)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007-P-001294
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.